JFL Life SciencesNSE:JFLLIFE +3.33%69 Interest Coverage is 7.26 as of Mar. 2025, which is 199% above its 10-year median of 2.43. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 69/100 and a GF Value™ of ₹35.66 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 686 Drug Manufacturers companies, JFL Life Sciences ranks worse than 61.52% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. JFL Life Sciences's
Operating Income
for the
six
months ended in Mar. 2025 was ₹72.1 Mil. JFL Life Sciences's Interest Expense for the
six
months ended in Mar. 2025 was ₹-9.9 Mil.
JFL Life Sciences's interest coverage for the quarter that ended in Mar. 2025 was 7.26.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for JFL Life Sciences's Interest Coverage or its related term are showing as below:
NSE:JFLLIFE'
s Interest Coverage Range Over the Past 10 Years
Min: 1.46 Med: 2.43 Max: 7.26
Current: 7.26
NSE:JFLLIFE's Interest Coverage is ranked worse than 61.52% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs NSE:JFLLIFE: 7.26
JFL Life Sciences (NSE:JFLLIFE) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
JFL Life Sciences Interest Coverage Related Terms
JFL Life Sciences Interest Coverage Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:JFLLIFE vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a Interest Coverage of 7.26 as of Mar. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on JFL Life Sciences and its competitors. This is 199% above median its historical median of 2.43. Over the past decade, JFL Life Sciences' Interest Coverage has ranged from 1.46 to 7.26. According to the industry distribution chart, JFL Life Sciences ranks #422 out of 686 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is JFL Life Sciences' Interest Coverage too high?
JFL Life Sciences' current Interest Coverage of 7.26 is 199% above median its 10-year median of 2.43. Over the past 10 years, this metric has ranged from a low of 1.46 to a high of 7.26. The Drug Manufacturers industry median Interest Coverage is 12.73. JFL Life Sciences' value of 7.26 is 42.9% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #422 out of 686 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #422 out of 686 companies for Interest Coverage. This places JFL Life Sciences in the lower half of its industry. The industry median Interest Coverage is 12.73. JFL Life Sciences' value of 7.26 is 42.9% below this benchmark. Historically, JFL Life Sciences' own Interest Coverage has ranged from 1.46 to 7.26 over the past decade. While the company's 10-year median is 2.43 vs. the industry median of 12.73, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current Interest Coverage of 7.26 is 42.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current Interest Coverage is 7.26, which is 199% above median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.66, compared to a current price of ₹9.30 — trading 73.9% below its estimated fair value. The current Interest Coverage is 7.26, which is 199% above median its 10-year median of 2.43 and 42.9% below the Drug Manufacturers industry median of 12.73. JFL Life Sciences' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Interest Coverage is 7.26 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹9.30 is trading 73.9% below its estimated GF Value™ of ₹35.66.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
Interest Coverage: 7.26 (199% above median its 10-year median of 2.43)
GF Value™: ₹35.66 vs. price of ₹9.30 (73.9% below fair value)
Industry Position: 42.9% below the Drug Manufacturers median (#422 of 686)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
69GF Score
Get the complete analysis for NSE:JFLLIFE
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 